ECP 2019 Final Programme

Monday, 9 Sept 181 ECP 2019 · Nice Breakfast and Luncheon Industry Symposia 003 13:25–13:50 Dissecting the key parameters underpin- ning exceptional execution of TMB analysis Eun-Ang Raiber, United Kingdom 004 13:50–14:15 TMB standardisation and harmonisation: recommendations for consistent TMB assessment across assays and centres Albrecht Stenzinger, Germany 005 14:15–14:30 Q&A Paul Hofman, France LS-04 Industry Symposium 13:00–14:30 Clio Transition to an effective and complete digital pathology workflow (3DHistech) Chair: Marianne Tinguely, Switzerland 001 Now, where is the AI that was promised to support us? Felix Faber, Switzerland 002 Implementation of virtual routine diagnos- tics for dermatopathology and fish Marianne Tinguely, Switzerland 003 Scanner for routine diagnostics: selection process in practice Witold Rezner, Switzerland 004 Context-intelligent deep learning for pathology and translational research Johan Lundin, Switzerland Platform for development of deep learning- based algorithms Sami Blom, Switzerland e Monday, 9 September 2019 BRM-01 Industry Symposium 07:15–08:15 Hermès Genomic profiling for driver mutations in cancer: NTRK gene fusions (Bayer) Chair: Reinhard Büttner, Germany 001 07:15–07:20 Welcome and introduction Reinhard Büttner, Germany 002 07:20–07:30 Novel genetic markers: NTRK gene fusions Giuseppe Viale, Italy 003 07:30–07:45 Developments in driver mutation detection: focus on NTRK gene fusions Reinhard Büttner, Germany 004 07:45–08:05 Interactive case session Reinhard Büttner, Germany Giuseppe Viale, Italy 005 08:05–08:15 Q&A Reinhard Büttner, Germany Giuseppe Viale, Italy LS-10 Industry Symposium 13:00–14:30 Athéna Transforming patient care through diagnostic innovation: liquid biopsies & clinical decision support (Roche) Chair: Marc Denis, France 001 13:00–13:05 Welcome and introduction Marc Denis, France 002 13:05–13:30 Clinical utility of liquid biopsy across technologies Marc Denis, France 003 13:30–13:55 Using ctDNA NGS as early response marker for immunotherapy in NSCLC Harry Groen, The Netherlands Sunday, 8 Sept